ADHD

The strongest confounders were family income, caregiver education, and ADHD polygenic risk scores for ADHD clinical range diagnoses.

Dr Feld highlights several formulations that are available to treat ADHD.

Dr Cutler shares treatment options for ADHD.

Dr Amann and other experts discuss importance of carefully weighing patient and parent expectations and goals when choosing treatment.

Drs Cerulli and Cutler discuss factors guiding treatment selection in ADHD.

ADHD experts discuss their approaches to management of ADHD in patients with comorbidities.

The most frequent psychiatric disorder that appeared in patients with ADHD was substance use disorder, followed by mood disorders, anxiety disorders, and personality disorders.

Psychiatrists share how they have incorporated telemedicine in the management of ADHD in their clinics.

Panelists share clinical burden of ADHD and how it impacts pediatric, adolescent and adult populations.

ADHD experts discuss presentation and underdiagnosis of ADHD in adults.

Drs Cerulli, Feld, Cutler, Mao, and Amann discuss prevalence and presentation of ADHD in pediatric, adolescent and adult populations.

A retrospective analysis of controlled drug dispensation shows conflicting rates of prescriptions to teenagers and young adults.

The results also show a bigger increase among adults between 2012-2017, which could be due to increased sensitivity of diagnosis.

Overall, 30.60% of pediatric patients who presented to the emergency department with mild head trauma were diagnosed with ADHD, compared to 8.96% of the control group.

ADHD and ODD dimensions were associated differently with different types of impulsivity, with unique patterns of network connectivity.

The results show pediatric patients with ADHD had a significantly higher risk of injuries requiring hospitalization compared to non-ADHD controls.

Older participants had smaller dual-task performance deficits for gait and texting speed in both the ADHD group and the control group.

Multivariate dimensional association scores resulted in an overall increase and normalization with age in the ADHD.

Prefrontal anodal transcranial direct current stimulation is more effective in treating ADHD compared to stimulation of the right inferior frontal gyrus.

The relative contribution of genetic influences to psychotic experiences was lower with increasing environmental exposure for paranoia, cognitive disorganization, grandiosity, and anhedonia.

Patients with dementias also had higher levels of NA-OXS, as did psychotic and bipolar disorders.

Mean inattention scores were about 5 points lower in the tDCS group compared to the sham treatment group.

The prevalence of suicidal was 10.9% in studies that included child-reported outcomes for child only and 10.4% for child and parent combined.

The patients prescribed stimulants were more likely to not have coexisting conditions than those treated with A2A.

Patients with autism had a fivefold increase in adjusted relative risk of self-harm.

Dr. Amy Licis details recent observations regarding potential underlying neurobiological reasons for sleep disturbance in pediatric patients with ADHD or autism.

Sleep issues are prevalent among children with autism or ADHD and both these common disorders are increasing. Any provider working with children is most likely going to encounter patients struggling with sleep.

Theresa R. Cerulli, MD, discusses the known clinical profile and evidential potential of the newest non-stimulant ADHD drug for adults.

On the heels of the FDA approval of viloxazine extended-release capsules for adult ADHD, a neuropsychiatrist discusses the state of care and diagnosis among older patients.

The approval expands the indication for Qelbree to all patients with ADHD aged 6 years and older, and provides adult patients their first novel non-stimulant option in 20 years.